Prostate Cancer Metastatic
120
29
39
43
Key Insights
Highlights
Success Rate
81% trial completion
Published Results
19 trials with published results (16%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
8.3%
10 terminated out of 120 trials
81.1%
-5.4% vs benchmark
11%
13 trials in Phase 3/4
44%
19 of 43 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 43 completed trials
Clinical Trials (120)
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria
Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
Castrate Resistant Prostate Cancer Enhertu Therapy
Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)
Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer
18F-PSMA PET/CT Versus CT Alone in Assessment of Prostatic Cancer Patients
PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)
Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
177Lu-HTK03170 in mCRPC With PSMA Positive Disease
Dynamic 68Ga-PSMA and 18F-FDG PET/CT Analysis Prior to 177Lu-PSMA
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer